Literature DB >> 12627227

Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States.

Althea W McCormick1, Cynthia G Whitney, Monica M Farley, Ruth Lynfield, Lee H Harrison, Nancy M Bennett, William Schaffner, Arthur Reingold, James Hadler, Paul Cieslak, Matthew H Samore, Marc Lipsitch.   

Abstract

Resistance of Streptococcus pneumoniae to antibiotics is increasing throughout the United States, with substantial variation among geographic regions. We show that patterns of geographic variation are best explained by the intensity of selection for resistance, which is reflected by differences between the proportions of resistance within individual serotypes, rather than by differences between the frequencies of particular serotypes. Using a mathematical transmission model, we analyzed temporal trends in the proportions of singly and dually resistant organisms and found that pneumococcal strains resistant to both penicillin and erythromycin are increasing faster than strains singly resistant to either. Using the model, we predict that by 1 July 2004, in the absence of a vaccine, 41% of pneumococci at the Centers for Disease Control and Prevention (CDC)'s Active Bacterial Core surveillance (ABCs) sites, taken together, will be dually resistant, with 5% resistant to penicillin only and 5% to erythromycin only.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627227     DOI: 10.1038/nm839

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  68 in total

1.  European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach.

Authors:  R H Vander Stichele; M M Elseviers; M Ferech; S Blot; H Goossens
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 3.  Development of adjunctive therapies for bacterial meningitis and lessons from knockout mice.

Authors:  Robert Paul; Uwe Koedel; Hans-Walter Pfister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 4.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

5.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine.

Authors:  Marc Lipsitch; Keith O'Neill; Derrick Cordy; Boris Bugalter; Krzysztof Trzcinski; Claudette M Thompson; Richard Goldstein; Stephen Pelton; Heather Huot; Valerie Bouchet; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

7.  Clonal success of piliated penicillin nonsusceptible pneumococci.

Authors:  K Sjöström; C Blomberg; J Fernebro; J Dagerhamn; E Morfeldt; M A Barocchi; S Browall; M Moschioni; M Andersson; F Henriques; B Albiger; Rino Rappuoli; S Normark; B Henriques-Normark
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-20       Impact factor: 11.205

8.  Coinfection Dynamics of Two Diseases in a Single Host Population.

Authors:  Daozhou Gao; Travis C Porco; Shigui Ruan
Journal:  J Math Anal Appl       Date:  2016-04-19       Impact factor: 1.583

9.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial.

Authors:  Girdhar Agarwal; Shally Awasthi; S K Kabra; Annapurna Kaul; Sunit Singhi; Stephen D Walter
Journal:  BMJ       Date:  2004-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.